Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 2/20 | 0.34 |
| ▸ | CTSK | P43235 | 2/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2441316 | 0.93 | TGM2 (0.33) | TGM2CTSKCTSLCTSBCTSS | |
| SCHEMBL2444816 | 0.84 | DRD2 (0.35) | TGM2CTSKCTSLCTSBCTSS | |
| SCHEMBL12299571 | 0.84 | DRD2 (0.35) | TGM2CTSKCTSLCTSBCTSS | |
| SCHEMBL2441782 | 0.81 | CTSL (0.36) | TGM2CTSL | |
| SCHEMBL2440601 | 0.80 | TGM2 (0.33) | TGM2SLC6A4DRD2HTR2AHTR7 | |
| SCHEMBL12299566 | 0.78 | TGM2 (0.33) | TGM2CTSKCTSLCTSBCTSS | |
| SCHEMBL2441314 | 0.78 | TGM2 (0.33) | TGM2CTSKCTSLCTSBCTSS | |
| SCHEMBL2446124 | 0.78 | CTSL (0.42) | TGM2CTSL | |
| SCHEMBL2445839 | 0.75 | XIAP (0.32) | SLC6A4DRD2HTR2AHTR7KCNH2 | |
| SCHEMBL12299725 | 0.73 | TGM2 (0.33) | TGM2CTSKCTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399683-B2 | IAP inhibitors | TETRALOGIC PHARMACEUTICALS (US) | 2013-03-19 | — | — | US | disclosed |
| US-20110237517-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237517-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | TGM2 2702/4885CTSK 320/4885CTSL 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.